Inventor · disambiguated record
Christopher U. Missling
Also filed as: MISSLING CHRISTOPHER U
19 granted patents·8 pending applications·30 citations·filing 2016–2025
92Inventor score
Top patents by PatentIndex Score
27 records- 0195US11446275B2Neurodevelopmental disorder therapyANAVEX LIFE SCIENCES CORP·Filed 2021·Granted Sep 20, 2022·3 cites·20 claims
- 0294US11813242B2A2-73 as a therapeutic for insomnia, anxiety, and agitationANAVEX LIFE SCIENCES CORP·Filed 2022·Granted Nov 14, 2023·2 cites·14 claims
- 0392US11839600B2Neurodevelopmental disorder therapyANAVEX LIFE SCIENCES CORP·Filed 2022·Granted Dec 12, 2023·1 cites·20 claims
- 0490US10813907B2A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapyANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Oct 27, 2020·4 cites·3 claims
- 0590US10507196B2Neurodevelopmental disorder therapyANAVEX LIFE SCIENCES CORP·Filed 2017·Granted Dec 17, 2019·8 cites·8 claims
- 0689US11337953B2A2-73 as a therapeutic for insomnia, anxiety, and agitationANAVEX LIFE SCIENCES CORP·Filed 2017·Granted May 24, 2022·3 cites·10 claims
- 0787US11622955B2Sigma-1 receptor agonist systolic blood pressure therapyANAVEX LIFE SCIENCES CORP·Filed 2018·Granted Apr 11, 2023·2 cites·22 claims
- 0887US10888543B2Neurodevelopmental disorder therapyANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Jan 12, 2021·4 cites·24 claims
- 0984US12285403B2A2-73 as a therapeutic for insomnia, anxiety and agitationANAVEX LIFE SCIENCES CORP·Filed 2023·Granted Apr 29, 2025·0 cites·20 claims
- 1083US2024066003A1Neurodevelopmental disorder therapyANAVEX LIFE SCIENCES CORP·Filed 2023·Application pending·0 cites
- 1180US12280034B2Sigma-1 receptor agonist systolic blood pressure therapyANAVEX LIFE SCIENCES CORP·Filed 2022·Granted Apr 22, 2025·0 cites·21 claims
- 1280US11071723B2Treatment of cardiac dysfunctionANAVEX LIFE SCIENCES CORP·Filed 2018·Granted Jul 27, 2021·2 cites·14 claims
- 1378US2025064772A1Treatment of cardiac dysfunctionANAVEX LIFE SCIENCES CORP·Filed 2024·Application pending·0 cites
- 1476US2025319057A1A2-73 as a therapeutic for insomnia, anxiety and agitationANAVEX LIFE SCIENCES CORP·Filed 2025·Application pending·0 cites
- 1573US11896590B2Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereofANAVEX LIFE SCIENCES CORP·Filed 2021·Granted Feb 13, 2024·0 cites·20 claims
- 1673US2025115566A1A2-73 crystalline polymorph compositions of matter and methods of use thereofANAVEX LIFE SCIENCES CORP·Filed 2024·Application pending·0 cites
- 1772US12180174B2A2-73 crystalline polymorph compositions of matter and methods of use thereofANAVEX LIFE SCIENCES CORP·Filed 2022·Granted Dec 31, 2024·0 cites·7 claims
- 1871US12138240B2Treatment of cardiac dysfunctionANAVEX LIFE SCIENCES CORP·Filed 2021·Granted Nov 12, 2024·0 cites·16 claims
- 1971US11690821B2A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapyANAVEX LIFE SCIENCES CORP·Filed 2020·Granted Jul 4, 2023·0 cites·20 claims
- 2071US2025281447A1Sigma-1 receptor agonist systolic blood pressure therapyANAVEX LIFE SCIENCES CORP·Filed 2025·Application pending·0 cites
- 2169US10195192B2Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereofMISSLING CHRISTOPHER U·Filed 2016·Granted Feb 5, 2019·1 cites·17 claims
- 2268US11498908B2A2-73 crystalline polymorph compositions of matter and methods of use thereofANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Nov 15, 2022·0 cites·29 claims
- 2366US2025325514A1Optimized sigma-1 agonist method of responder selection and treatmentANAVEX LIFE SCIENCES CORP·Filed 2025·Application pending·0 cites
- 2465US10933062B2Analgesic therapeutic and method, 1-(3-4(((1 R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereofANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Mar 2, 2021·0 cites·21 claims
- 2563US2024417798A1Therapy selection and treatment of neurodegenerative disordersANAVEX LIFE SCIENCES CORP·Filed 2022·Application pending·0 cites
- 2660US12383526B2Optimized sigma-1 agonist method of responder selection and treatmentANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Aug 12, 2025·0 cites·8 claims
- 2752US2022249427A1Anavex2-73 for the treatment of genetic neurodevelopmental disordersANAVEX LIFE SCIENCES CORP·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christopher U. Missling files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →